Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Immune Tolerance
AddedFeb 18, 2024
UpdatedJun 18, 2026
Immune Tolerance

Immune Tolerance

Developing genetic tests as a tool to reduce hospital infection risks.

HQ
Menlo Park, CA, US
Founded
2007
Overview
Compare
Fundraising
Employees

Immune Tolerance focuses on developing genetic tests to reduce hospital infection risks. Their mission is to enhance patient safety through innovative genetic solutions. They aim to serve the healthcare market by providing tools that help identify and mitigate infection risks in hospital settings.

The company has made significant strides in the field of genetic testing, contributing to improved patient outcomes and reduced infection rates in hospitals. Their work has garnered attention and support from key stakeholders in the healthcare industry, underscoring their impact and potential for future growth.

Immune Tolerance - Similar Companies

ImmuneTarget logo

ImmuneTarget

Geneticure logo

Geneticure

geneticure.com

Geneicd logo

Geneicd

ImmuneID logo

ImmuneID

Gene Solutions logo

Gene Solutions

Tolerion logo

Tolerion

Juno Diagnostics logo

Juno Diagnostics

Invitae logo

Invitae

invitae.com

VitaPath Genetics logo

VitaPath Genetics

Allelica logo

Allelica

allelica.com

Innate Immunity logo

Innate Immunity

Iverson Genetic Diagnostics logo

Iverson Genetic Diagnostics

ImmunArtes logo

ImmunArtes

Gentec logo

Gentec

Fulgent Diagnostics logo

Fulgent Diagnostics

Immune Tolerance - Quick Facts

Who are Immune Tolerance's competitors?

Companies similar to Immune Tolerance include ImmuneTarget, Geneticure, Geneicd and ImmuneID.

When was Immune Tolerance founded?

Immune Tolerance was founded in 2007.

Where is Immune Tolerance's headquarters located?

Immune Tolerance's headquarters is located in Menlo Park, CA, US.

When was Immune Tolerance's last funding round?

Immune Tolerance's most recent funding round was for $180k (USD) in February 2015.

How much has Immune Tolerance raised to-date?

As of Feb 1, 2015, Immune Tolerance has raised a total of $180k (USD).

How many employees does Immune Tolerance have?

Immune Tolerance has 75 employees as of Feb 4, 2024.

Immune Tolerance - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Genetic Tests
Tags
  • Data
  • Healthtech
NAICS
  • 621000Ambulatory Health Care Services
  • 621400Outpatient Care Centers
  • 621490Other Outpatient Care Centers
  • 621491HMO Medical Centers
  • 620000Health Care and Social Assistance
SIC
  • 8010Offices And Clinics Of Doctors Of Medicine
  • 8011Offices And Clinics Of Doctors Of Medicine
  • 8000Health Services
Show 10 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research